



GOV. MSG. NO. 1296

EXECUTIVE CHAMBERS  
HONOLULU

DAVID Y. IGE  
GOVERNOR

July 1, 2015

The Honorable Ronald D. Kouchi,  
President  
and Members of the Senate  
Twenty-Eighth State Legislature  
State Capitol, Room 409  
Honolulu, Hawai'i 96813

The Honorable Joseph M. Souki,  
Speaker and Members of the  
House of Representatives  
Twenty-Eighth State Legislature  
State Capitol, Room 431  
Honolulu, Hawai'i 96813

Dear President Kouchi, Speaker Souki, and Members of the Legislature:

This is to inform you that on July 1, 2015, the following bill was signed into law:

SB1131 SD2 HD2 CD1

RELATING TO THE UNIFORM CONTROLLED  
SUBSTANCES ACT  
**ACT 195 (15)**

Sincerely,

A handwritten signature in black ink that reads "David Y. Ige".

DAVID Y. IGE  
Governor, State of Hawai'i

RECEIVED  
SENATE  
OFFICE OF THE PRESIDENT

RECEIVED  
THE SENATE  
CLERK'S OFFICE  
STATE OF HAWAII

'15 JUL -1 P3:12

'15 JUL -1 P4:18

*John A. Burns*

# A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

**BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:**

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is  
2 amended by amending subsections (f) and (g) to read as follows:

3 "(f) Stimulants. Unless specifically excepted or unless  
4 listed in another schedule, any material, compound, mixture, or  
5 preparation which contains any quantity of the following  
6 substances having a stimulant effect on the central nervous  
7 system, including its salts, isomers, and salts of isomers:

- 8 (1) Aminorex;
- 9 (2) Cathinone;
- 10 (3) Fenethylamine;
- 11 (4) Methcathinone;
- 12 (5) N-ethylamphetamine;
- 13 (6) 4-methylaminorex;
- 14 (7) N,N-dimethylamphetamine; and
- 15 (8) Substituted cathinones, any compound, except bupropion  
16 or compounds listed under a different schedule,  
17 structurally derived from 2-aminopropan-1-ol by  
18 substitution at the 1-position with either phenyl,



1 naphthyl, or thiophene ring systems, whether or not  
2 the compound is further modified in any of the  
3 following ways:

- 4 (A) By substitution in the ring system to any extent  
5 with alkyl, alkylendioxy, alkoxy, haloalkyl,  
6 hydroxyl, or halide substituents, whether or not  
7 further substituted in the ring system by one or  
8 more other univalent substituents;
- 9 (B) By substitution at the 3-position with an acyclic  
10 alkyl substituent; or
- 11 (C) By substitution at the 2-amino nitrogen atom with  
12 alkyl, dialkyl, benzyl, or methoxybenzyl groups,  
13 or by inclusion of the 2-amino nitrogen atom in a  
14 cyclic structure.

15 Some other trade names: Mephedrone (2-methylamino-1-  
16 p-tolylpropan-1-one), also known as 4-  
17 methylmethcathinone (4-MMC), methylephedrone or MMCAT;  
18 Methylenedioxyprovalerone (MDPV, MDPK); [and]  
19 methylone or 3,4-methylenedioxymethcathinone[-]; and  
20 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-  
21 one, monohydrochloride, also known as Ethylone, bk-



1 MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-  
2 ethylcathinone; bk-Methylenedioxyethylamphetamine.

3 (g) Any of the following cannabinoids, their salts,  
4 isomers, and salts of isomers, unless specifically excepted,  
5 whenever the existence of these salts, isomers, and salts of  
6 isomers is possible within the specific chemical designation:

- 7 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols  
8 naturally contained in a plant of the genus Cannabis  
9 (cannabis plant), as well as synthetic equivalents of  
10 the substances contained in the plant, or in the  
11 resinous extractives of Cannabis, sp. or synthetic  
12 substances, derivatives, and their isomers with  
13 similar chemical structure and pharmacological  
14 activity to those substances contained in the plant,  
15 such as the following: Delta 1 cis or trans  
16 tetrahydrocannabinol, and their optical isomers; Delta  
17 6 cis or trans tetrahydrocannabinol, and their optical  
18 isomers; and Delta 3,4 cis or trans-  
19 tetrahydrocannabinol, and its optical isomers (since  
20 nomenclature of these substances is not  
21 internationally standardized, compounds of these



- 1 structures, regardless of numerical designation of  
2 atomic positions, are covered);
- 3 (2) Naphthoylindoles; meaning any compound containing a  
4 3-(1-naphthoyl) indole structure with substitution at  
5 the nitrogen atom of the indole ring by a alkyl,  
6 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
7 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
8 ethyl group, whether or not further substituted in the  
9 indole ring to any extent and whether or not  
10 substituted in the naphthyl ring to any extent;
- 11 (3) Naphthylmethylinindoles; meaning any compound containing  
12 a 1H-indol-3-yl-(1-naphthyl) methane structure with  
13 substitution at the nitrogen atom of the indole ring  
14 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
15 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or  
16 2-(4-morpholinyl) ethyl group whether or not further  
17 substituted in the indole ring to any extent and  
18 whether or not substituted in the naphthyl ring to any  
19 extent;
- 20 (4) Naphthoylpyrroles; meaning any compound containing a  
21 3-(1-naphthoyl) pyrrole structure with substitution at



1 the nitrogen atom of the pyrrole ring by a alkyl,  
2 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
3 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
4 ethyl group whether or not further substituted in the  
5 pyrrole ring to any extent, whether or not substituted  
6 in the naphthyl ring to any extent;

7 (5) Naphthylmethylenes; meaning any compound containing  
8 a naphthylideneindene structure with substitution at  
9 the 3-position of the indene ring by a alkyl,  
10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
11 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
12 ethyl group whether or not further substituted in the  
13 indene ring to any extent, whether or not substituted  
14 in the naphthyl ring to any extent;

15 (6) Phenylacetylindoles; meaning any compound containing a  
16 3-phenylacetylindole structure with substitution at  
17 the nitrogen atom of the indole ring by a alkyl,  
18 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
19 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
20 ethyl group whether or not further substituted in the



- 1 indole ring to any extent, whether or not substituted  
2 in the phenyl ring to any extent;
- 3 (7) Cyclohexylphenols; meaning any compound containing a  
4 2-(3-hydroxycyclohexyl) phenol structure with  
5 substitution at the 5-position of the phenolic ring by  
6 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
7 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or  
8 2-(4-morpholinyl) ethyl group whether or not  
9 substituted in the cyclohexyl ring to any extent;
- 10 (8) Benzoylindoles; meaning any compound containing a  
11 3-(benzoyl) indole structure with substitution at the  
12 nitrogen atom of the indole ring by a alkyl,  
13 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
14 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
15 ethyl group whether or not further substituted in the  
16 indole ring to any extent and whether or not  
17 substituted in the phenyl ring to any extent;
- 18 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)  
19 pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-  
20 [~~naphthalenylmethanone~~] naphthalenylmethanone (another  
21 trade name is WIN 55,212-2);





- 1 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-  
2 methyloctan-2-yl)-6a,7,10,10a-  
3 tetrahydrobenzo[c]chromen-1-ol (other trade names are:  
4 HU-210 and HU-211);
- 5 (11) Tetramethylcyclopropanoylindoles; meaning any compound  
6 containing a 3-tetramethylcyclopropanoylindole  
7 structure with substitution at the nitrogen atom of  
8 the indole ring by an alkyl, haloalkyl, cyanoalkyl,  
9 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
10 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,  
11 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
12 morpholinyl)methyl, or tetrahydropyranylmethyl group,  
13 whether or not further substituted in the indole ring  
14 to any extent and whether or not substituted in the  
15 tetramethylcyclopropyl ring to any extent;
- 16 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,  
17 its optical, positional, and geometric isomers, salts,  
18 and salts of isomers (Other names: APINACA, AKB48);
- 19 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its  
20 optical, positional, and geometric isomers, salts, and  
21 salts of isomers (Other names: PB-22; QUPIC);



- 1 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-  
2 carboxylate, its optical, positional, and geometric  
3 isomers, salts, and salts of isomers (Other names: 5-  
4 fluoro-PB-22; 5F-PB-22);
- 5 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-  
6 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,  
7 positional, and geometric isomers, salts, and salts of  
8 isomers (Other names: AB-FUBINACA); [~~and~~]
- 9 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-  
10 indazole-3-carboxamide, its optical, positional, and  
11 geometric isomers, salts, and salts of isomers (Other  
12 names: ADB-PINACA) [~~-~~];
- 13 (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-  
14 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its  
15 optical, positional, and geometric isomers, salts, and  
16 salts of isomers (Other names: AB-CHMINACA);
- 17 (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-  
18 indazole-3-carboxamide, and geometric isomers, salts,  
19 and salts of isomers (Other names: AB-PINACA);



- 1        (19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-  
2        yl)methanone, and geometric isomers, salts, and salts  
3        of isomers (Other names: THJ-2201);
- 4        (20) Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-  
5        valinate, and geometric isomers, salts, and salts of  
6        isomers (other names: FUB-AMB);
- 7        (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
8        carboxamido)-3-methylbutanoate, and geometric isomers,  
9        salts, and salts of isomers (Other names: 5-fluoro-  
10       AMB, 5-fluoro-AMP);
- 11       (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-  
12       indazole-3-carboxamide, and geometric isomers, salts,  
13       and salts of isomers (Other names: AKB48 N-(5-  
14       fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl  
15       analog, 5F-APINACA);
- 16       (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and  
17       geometric isomers, salts, and salts of isomers (Other  
18       names: STS-135, 5F-APICA; 5-fluoro-APICA); and
- 19       (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-  
20       caboxylate, and geometric isomers, salts, and salts of  
21       isomers (Other names: NM2201)."



1 SECTION 2. Section 329-18, Hawaii Revised Statutes, is  
2 amended by amending subsection (e) to read as follows:

3 "(e) Narcotic drugs. Unless specifically excepted or  
4 unless listed in another schedule, any material, compound,  
5 mixture, or preparation containing any of the following narcotic  
6 drugs, or their salts, or alkaloid, in limited quantities as set  
7 forth below:

8 (1) Not more than 1.8 grams of codeine, or any of its  
9 salts, per 100 milliliters or not more than 90  
10 milligrams per dosage unit, with an equal or greater  
11 quantity of an isoquinoline alkaloid of opium;

12 (2) Not more than 1.8 grams of codeine, or any of its  
13 salts, per 100 milliliters or not more than 90  
14 milligrams per dosage unit, with one or more active,  
15 nonnarcotic ingredients in recognized therapeutic  
16 amounts;

17 ~~[(3) Not more than 300 milligrams of dihydrocodeinone~~  
18 ~~(Hydrocodone), or any of its salts, per 100~~  
19 ~~milliliters or not more than 15 milligrams per dosage~~  
20 ~~unit, with a fourfold or greater quantity of an~~  
21 ~~isoquinoline alkaloid of opium provided that these~~



- 1           ~~narcotic drugs shall be monitored pursuant to section~~  
2           ~~329-101,~~
- 3           ~~(4) Not more than 300 milligrams of dihydrocodeinone~~  
4           ~~(Hydrocodone), or any of its salts per 100 milliliters~~  
5           ~~or not more than 15 milligrams per dosage unit, with~~  
6           ~~one or more active, nonnarcotic ingredients in~~  
7           ~~recognized therapeutic amounts provided that these~~  
8           ~~narcotic drugs shall be monitored pursuant to section~~  
9           ~~329-101,~~
- 10          ~~(5)]~~ (3) Not more than 1.8 grams of dihydrocodeine, or any  
11           of its salts, per 100 milliliters or not more than 90  
12           milligrams per dosage unit, with one or more active,  
13           nonnarcotic ingredients in recognized therapeutic  
14           amounts;
- 15          ~~(6)]~~ (4) Not more than 300 milligrams of ethylmorphine, or  
16           any of its salts, per 100 milliliters or not more than  
17           15 milligrams per dosage unit, with one or more  
18           ingredients in recognized therapeutic amounts;
- 19          ~~(7)]~~ (5) Not more than 500 milligrams of opium per 100  
20           milliliters or per 100 grams, or not more than 25  
21           milligrams per dosage unit, with one or more active

1 nonnarcotic ingredients in recognized therapeutic  
2 amounts;

3 ~~[(+8)]~~ (6) Not more than 50 milligrams of morphine or any of  
4 its salts, per 100 milliliters or per 100 grams with  
5 one or more active, nonnarcotic ingredients in  
6 recognized therapeutic amounts; and

7 ~~[(+9)]~~ (7) Buprenorphine."

8 SECTION 3. Section 329-20, Hawaii Revised Statutes, is  
9 amended as follows:

10 1. By amending subsection (b) to read:

11 "(b) Depressants. Any material, compound, mixture, or  
12 preparation which contains any quantity of the following  
13 substances, including its salts, isomers, esters, ethers, and  
14 salts of isomers, whenever the existence of these isomers,  
15 esters, ethers, and salts is possible within the specific  
16 chemical designation, that has a degree of danger or probable  
17 danger associated with a depressant effect on the central  
18 nervous system:

- 19 (1) Alprazolam;
- 20 (2) Barbital;
- 21 (3) Bromazepam;



- 1 (4) Butorphanol;
- 2 (5) Camazepam;
- 3 (6) Carisoprodol;
- 4 (7) Chloral betaine;
- 5 (8) Chloral hydrate;
- 6 (9) Chlordiazepoxide;
- 7 (10) Clobazam;
- 8 (11) Clonazepam;
- 9 (12) Clorazepate;
- 10 (13) Clotiazepam;
- 11 (14) Cloxazolam;
- 12 (15) Delorazepam;
- 13 (16) Dichloralphenazone (Midrin);
- 14 (17) Diazepam;
- 15 (18) Estazolam;
- 16 (19) Ethchlorvynol;
- 17 (20) Ethinamate;
- 18 (21) Ethyl loflazepate;
- 19 (22) Fludiazepam;
- 20 (23) Flunitrazepam;
- 21 (24) Flurazepam;



- 1 (25) Fospropofol (Lusedra);
- 2 (26) Halazepam;
- 3 (27) Haloxazolam;
- 4 (28) Ketazolam;
- 5 (29) Loprazolam;
- 6 (30) Lorazepam;
- 7 (31) Lormetazepam;
- 8 (32) Mebutamate;
- 9 (33) Medazepam;
- 10 (34) Meprobamate;
- 11 (35) Methohexital;
- 12 (36) Methylphenobarbital (mephorbarbital);
- 13 (37) Midazolam;
- 14 (38) Nimetazepam;
- 15 (39) Nitrazepam;
- 16 (40) Nordiazepam;
- 17 (41) Oxazepam;
- 18 (42) Oxazolam;
- 19 (43) Paraldehyde;
- 20 (44) Petrichloral;
- 21 (45) Phenobarbital;





- 1 (46) Pinazepam;
- 2 (47) Prazepam;
- 3 (48) Quazepam;
- 4 (49) Suvorexant;
- 5 [~~49~~] (50) Temazepam;
- 6 [~~50~~] (51) Tetrazepam;
- 7 [~~51~~] (52) Triazolam;
- 8 [~~52~~] (53) Zaleplon;
- 9 [~~53~~] (54) Zolpidem; and
- 10 [~~54~~] (55) Zopiclone (Lunesta)."

11 2. By amending subsection (g) to read:

12 "(g) Narcotic drugs. . Unless specifically excepted or  
13 unless listed in another schedule, any material, compound,  
14 mixture, or preparation containing any of the following narcotic  
15 drugs, or their salts calculated as the free anhydrous base or  
16 alkaloid, in limited quantities as set forth below:

- 17 (1) Not more than one milligram of difenoxin and not less  
18 than twenty-five micrograms of atropine sulfate per  
19 dosage unit; [~~and~~]
- 20 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-  
21 diphenyl-3-methyl-2-propionoxybutane) [~~-~~]; and




1        (3) 2-[(dimethylamino)methyl]-1-(3-  
2        methoxyphenyl)cyclohexanol, its salts, optical and  
3        geometric isomers and salts of these isomers  
4        (including tramadol)."

5        SECTION 4. Statutory material to be repealed is bracketed  
6 and stricken. New statutory material is underscored.

7        SECTION 5. This Act shall take effect upon its approval.

APPROVED this        1        day of        JUL        , 2015



GOVERNOR OF THE STATE OF HAWAII